SUBSCRIBE
SUBSCRIBE

CNS Pharmaceuticals, Inc.

NEWS
Image of Houston downtown park and skyline in the morning
Business
Houston’s Life Sciences Scene Continues Boosting Its Reputation
While Houston isn’t yet on the same level as major life sciences hubs, it has plenty to offer and room to grow, according to CNS Pharmaceuticals, RadioMedix and Greater Houston Partnership executives.
March 13, 2025
 · 
6 min read
 · 
Angela Gabriel
IN THE PRESS
Business
CNS Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 15, 2022
 · 
9 min read
Business
CNS Pharmaceuticals Urges Shareholders to Vote in Favor of Proxy Proposals for the Upcoming Annual Meeting of Shareholders on July 27, 2022
July 25, 2022
 · 
5 min read
FDA
CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
June 23, 2022
 · 
7 min read
Lone Star Bio
CNS Pharmaceuticals Announces Presentation of Ongoing Potentially Pivotal Berubicin Clinical Trial Design at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
June 8, 2022
 · 
7 min read
Lone Star Bio
CNS Pharmaceuticals Announces Presentation at the H.C. Wainwright Global Investment Conference
May 24, 2022
 · 
2 min read
Lone Star Bio
CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
May 18, 2022
 · 
4 min read
Business
CNS Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 16, 2022
 · 
8 min read
Lone Star Bio
CNS Pharmaceuticals Receives Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
April 28, 2022
 · 
6 min read
Lone Star Bio
CNS Pharmaceuticals to Participate in the Virtual Investor Glioblastoma Multiforme (GBM) Spotlight Event
April 12, 2022
 · 
4 min read
Lone Star Bio
CNS Pharmaceuticals Receives Approval from France Ethics Committee and Competent Authority for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
April 6, 2022
 · 
6 min read
Load More
JOBS